The antiplatelet drug target in atherosclerotic diseases

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 6, Issue 1, 2006, Pages 43-55

  Belcher, P R ^a   Drake Holland, A J ^b   Noble, M I M ^c  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b ROBERT GORDON UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Acalcaemia; Atherothrombosis; Cardioprotection; Macroaggregation; Microaggregation; Platelets; Serotonin; Shear; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; CALCIUM ION; CITRIC ACID; CLOPIDOGREL; COLLAGEN; CYCLOOXYGENASE 1; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EDETIC ACID; ENOXAPARIN; FIBRIN; FIBRINOGEN RECEPTOR; HEPARIN; HIRUDIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; LISINOPRIL; LOSARTAN; NONSTEROID ANTIINFLAMMATORY AGENT; PRAVASTATIN; PURINE P2Y12 RECEPTOR; SEROTONIN; SEROTONIN 2 ANTAGONIST; SIMVASTATIN; THROMBIN INHIBITOR; UNINDEXED DRUG; VALSARTAN;

ANTICOAGULANT THERAPY; ARTERY INJURY; ARTERY THROMBOSIS; ATHEROSCLEROSIS; BLEEDING; BLOOD CLOTTING PARAMETERS; BLOOD SAMPLING; CHEMOPROPHYLAXIS; DRUG TARGETING; EXTRACELLULAR CALCIUM; HEART PROTECTION; HUMAN; IN VIVO STUDY; NONHUMAN; PATIENT MONITORING; POSITIVE FEEDBACK; REVIEW; SHEAR STRESS; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOGENESIS; THROMBOSIS; VASCULAR DISEASE;

EID: 33744484766     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152906776092631     Document Type: Review

References (171)

1. Pleiner, J., Schaller, G., Mittermayer, F., Zorn, S., Marsik, C. Simvastatin prevents vascular hyporeactivity during inflammation. Circulation 2004, 110, 3349-3354.
2. Huo, Y., Ley, F. Platelet activation in atherosclerosis. Trends in Cardiovas. Dis., 2004, 14, 18-22.
3. 2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N. Eng. J. Med.,
4. Meade, T., North, W., Chakrabarti, R., Stirling, Y., Haines, P., Thompson, S. G. Haemostatic function and cardiovascular death: early results of a prospective study. Lancet, 1980, i, 1050-1054.
5. Yarnell, J. W. G., Patterson, C. C., Sweetnam, P. M., Lowe, G. D. O. Haemostatic/inflammatory markers predict 10-year risk of IHD at least as well as lipids: the Caerphilly collaborative studies. Eur.H.J., 2004, 25, 1049-1056.
6. Fuster, V., Griggs, T. R. In Prog. Hemos. Thromb., Grune & Stratton: 1986, p 159-183.
7. Rosendaal, F. R., Varekamp, I., Smit, C., Brocker-Vriends, H. J. T., Dyck, H., Vandenbroucke, J. P., Hermans, J., Suurmeijer, T. P., Briet, E. Mortality and causes of death in Dutch haemophilliacs. Br. J. Haematol., 1989, 71, 71-76.
8. Noble, M. I. M. Overview: Thrombosis as a unitary hypothesis of cardiovascular risk. J. Cardiovas. Risk., 1995, 2, 177-179.
9. von Rokitansky, C. A manual of pathological anatomy. The Sydenham Society, 1852, 265-275.
10. von Rokitansky, C. In A Manual of Pathological Anatomy; Swaine, W., Sieveking, E., Moore, C., Day, G., Eds.; Blanchard & Lee: Philadelphia, 1855; Vol. 4, pp 198-207.
11. Anand, S. S., Yusuf, S. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. J. Am. Med. Assoc., 1999, 282, 2058-2067.
12. Brouwer, M. A., van den Bergh, P. J., Aengevaeren, W. R. Aspirin plus coumarin versus aspirin alone in prevention of reocclusion after fibrinolysis for acute myocardial infarction: Results of the antithrombotics in the prevention of reocclusion in coronary thrombolysis (APRICOT)-2 Trial. Circulation, 2002, 106, 659-666.
13. Hurlen, M., Abdelnoor, M., Smith, P., Erikssen, J., Arnesen, H. Warfarin, aspirin, or both after myocardial infarction. N. Eng. J. Med., 2002, 347, 1019-1022.
14. Smith, P., Arnesen, H., Holme, I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N. Eng. J. Med., 1990, 323, 147-152.
15. van Es, R. F., Jonker, J. J. C., Verheugt, F. W. A., Deckers, J. W., Grobbee, D. E. Antithrombotics in the secondary prevention of events in coronary thrombosis-2 (ASPECT-2) research group. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet, 2002, 360, 109-113.
16. Antman, E. A. The re-emergence of anticoagulation in coronary disease. Eur. H. J. 2004, 6 (Suppl B), B2-B8.
17. Wallentin, L. Oral direct thrombin inhibition for anticoagulation in coronary artery disease - focus on the ESTEEM trial. Eur. H. J., 2004, 6 (Suppl. B), B9-B14.
18. Peterson, J. L., Mahaffey, K. W., Hasselblad, V., Antman, E. M., Cohen, M.,Goodman, S. G., Langer, A., Blazing, M. A., LeMoigne-Amrani, A., de Lemos, J. A., Nessel, C. C., Harrington, R. A., Ferguson, J. J., Braunwald, E., Califf, R. M. Efficacy and bleeding complications among patients randomized to enoxiparin or unfractionated heparin for antithrombin therapy in mom-ST-Segment elevation acute coronary syndromes. J. Am. Med. Assoc., 2004, 292, 89-96.
19. SYNERGY Trial Investigators Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. J. Am. Med. Assoc., 2004, 292, 45-54.
20. Murithi, E. W., Belcher, P. R., Rao, J. N., Chaudhry, M. A., Nicol, D., Wheatley, D. J. The effects of heparin and extracorporeal circulation on platelet counts and platelet microaggregation during cardiopulmonary bypass. J. Thorac. Cardiovasc. Surg., 2000, 120, 538-543.
21. Thomson, C., Forbes, C. D., Prentice, C.R. The potentiation of platelet aggregation and adhesion by heparin in vitro and in vivo. Clin. Sci. Mol. Med., 1973, 45, 485-494.
22. Belcher, P. R., Murithi, E. W., Milne, E. M., Wanikiat, P., Wheatley, D. J., Armstrong, R. A. Heparin, platelet aggregation, neutrophils and cardiopulmonary bypass. Thromb. Res., 2000, 98, 249-256.
23. Khuri, S. F., Valeri, R., Loscalzo, J., Weinstein, M. J., Birjiniuk, V., Healey, N. A., MacGregor, H., Doursounian, M., Zolkewitz, M. A. Heparin causes platelet dysfunction and induces fibrinolysis before cardiopulmonary by pass. Ann. Thorac. Surg., 1995, 60, 1008-1014.
24. Besterman, E. M., Gillett, M. P. Heparin effects on plasma lysolecithin formation and platelet aggregation. Atherosclerosis 1973, 17, 503-513.
25. Murithi, E. W., Belcher, P. R., Day, S. P., Menys, V. C, Wheatley, D. J. Heparin induced platelet dysfunction and cardiopulmonary bypass. Ann. Thorac. Surg., 2000, 69, 1827-1832.
26. 14C]5- hydroxytryptamine release. B. J. Haematol., 1977, 36, 427-436.
27. Kestin, A. S., Valeri, C. R., Khuri, S. F., Loscalzo, J., Ellis, P. A., MacGregor, H., Birjiniuk, V., Ouimet, H., Pasche, B., Nelson, M. J., Benoit, E. E., Rodino, L. J., Barnard, M. R., Michelson, A., D. The platelet function defect of cardiopulmonary bypass. Blood, 1993, 82, 107-117.
28. Belcher, P. R., Muriithi, E. W., Day, S. P., Wheatley, D. J. Platelet aggregatory responses to low dose collagen are maintained in hirudin-anticoagulated whole blood for 24 hours when stored at room temperature. Platelets, 2001, 12, 34-36.
29. Murithi, E. W., Belcher, P. R., Menys, V. C., Chaudhry, M. A., Raco, L., Day, S. P., Wheatley, D. J. Quantitative detection of platelet aggregates in whole blood without fixation. Platelets, 2000, 11, 33-37.
30. Novotny, W. F., Maffi, T., Mehta, R. L., Milner, P. G. Identification of novel heparin-releasable proteins, as well as the cytokines midkine and pleiotrophin, in human postheparin plasma. Arterioscl. Thromb., 1993, 13, 1798-1805.
31. Pearce, G. A., Brown, K. F. Heat inhibition of in vitro lipolysis and 14C ibuprofen protein binding in plasma from heparinized uraemic subjects. Life Sci., 1983, 33, 1457-1466.
32. Zambon, A., Hashimoto, S. I., Brunzell, J. D. Analysis of techniques to obtain plasma for measurement of levels of free fatty acids. J. Lipid Res., 1993, 34, 1021-1028.
33. MacIntyre, D. E., Hoover, R. L., Smith, M., Steer, M., Lynch, C., Karnovsky, M. J., Salzman, E. W. Inhibition of platelet function by cis-unsaturated fatty acids. Blood, 1984, 63, 848-857.
34. Siafaka-Kapadai, A., Hanahan, D. An endogenous inhibitor of PAF-induced platelet aggregation, isolated from rat liver, has been identified as free fatty acid. Biochim. Biophys. Acta., 1993, 1166, 217-21.
35. Riddell, D. R., Graham, A. J., Owen, S. Apolipoprotein E inhibits platelet aggregation through the L- arginine:nitric oxide pathway. Implications for vascular disease. J. Biol. Chem., 1997, 272, 89-95.
36. Barrowcliffe, T. W., Merton, R. E., Gray, E., Thomas, D. P. Heparin and bleeding: an association with lipase release. Thromb. Haemo., 1988, 60, 434-436.
37. Besterman, E. M., Gillett, M. P. Inhibition of platelet aggregation by lysolecithin. Atherosclerosis, 1971, 14, 323-30.
38. Desai, K., Bruckdorfer, K. R., Hutton, R. A., Owen, J. S. Binding of apoE-rich high density lipoprotein particles by saturable sites on human blood platelets inhibits agonist-induced platelet aggregation. J. Lipid Res., 1989, 30, 831-840.
39. Murithi, E. W., Belcher, P. R., Day, S. P., Chaudhry, M. A., Caslake, M. J., Wheatley, D. J. Lipolysis generates platelet dysfunction after in vivo heparin administration. Clin. Sci., 2002, 103, 433-440.
40. Antiplatelet Trialist's Collaboration Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. B.M.J., 1994, 308, 81-106.
41. Antiplatelet Trialist's Collaboration Collaborative overview of randomised trials of antiplatelet therapy. II. Maintenance of vascular graft or arterial patency by antiplatelet therapy. B.M.J., 1994, 308, 159-168.
42. Antiplatelet Trialist's Collaboration Collaborative overview of randomised trials of antiplatelet therapy. III. Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. B.M.J., 1994, 308, 81-106.
43. Antiplatelet Trialists Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. B.M.J., 2002, 324, 71-86.
44. Bauer, M., Maschberger, P., Quek, L., Briddon, S., Dash, H., Weiss, M., Watson, S., Siess, W. Genetic and pharmacological analyses of involvement if Src-family, Syk and Btk kinases in platelet shape change. Thromb. Haemos., 2001, 85, 331-340.
45. Karlberg, K., Torfgard, K., Ahlner, J., Sylven, C. Dose-dependent effect of intravenous nitorglycerine on platelet aggregation, and correlation with plasma glyceryl dinitrate concentration in healthy men. Am. J. Cardiol., 1992, 69, 802-805.
46. Holmes, A., Chrikov, Y., Willoughby, S., Poropat, S., Pereira, J., Horowitz, J. Preservation of platelet responsiveness to nitroglycerine despite development of vascular nitrate tolerance. B. J. Pharmacol., 2005, 60, 355-363.
47. Golino, P., Capelli-Bigazzi, M., Ambrosio, G., Ragni, M., Russolillo, E., Condorelli, M., Chiarello, M. Endothelium-derived relaxing factor modulates platetlet aggregation in an in vivo model of recurrent platelet activation. Circ. Res., 1992, 71, 1447-1456.
48. Gudmundsdottir, I., McRobbie, S., Robinson, S., Newby, D., Megson, I. Sildenafil potentiates nitric oxide mediated inhibition of human platelet aggregation. Biochem. Biophys. Res. Comm., 2005, 337, 382-385.
49. Willoughby, S., Stewart, S., Holmes, A., Chirkov, Y., Horowitz, J. Platelet nitric oxide responsiveness: a novel prgonostic marker in acute coronary syndromes. Arterio. Thromb. Haemos. Vasc. Biol., 2006, 26, 0-0.
50. Furman, M., Barnard, M., Kreuger, L., Fox, M.,S hilale, E., Lessard, D., Marchese, P., Frelinger, A., Goldberg, R., Michelson, A., Benoit, S., Valeri, C., Borbone, M., Becker, R. Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. JAMA, 2001, 38, 1002-1006.
51. Nijm, J., Wikby, A., Tompa, A., Olsson, A., Jonasson, L. Circulating levels of proinflammatory cytokines and neutrophil-platelet aggregates in patients with coronary artery disease. Am. J. Cordial., 2005, 95, 452-456.
52. Zellar, J., Lenz, A., Eschenfelder, C., Zunker, P., Deuschl, G. Platelet-leukocyte interaction and platelet activation in acute stroke with and without preceding infection. Arterio. Thromb. Haemos. Vasc. Biol., 2005, 25, 1519-1523.
53. Faraday, N., Braunstein, J., Heldman, A., Bolton, E., Chiles, K., Gersenblith, G.,S chulman, S. Prospective evaluation of the relationship bewtween platelet-leukocytes conjugate formation and recurrent myocardial ischemia in patients with acute coronary syndromes. Platelets, 2004, 15, 9-14.
54. Chlopicki, S., Lomnicka, M., Gryhlewski, R. Obligatory role of lipid mediators in platelet-neutrophil adhesion. Thromb. Res., 2003, 110, 287-292.
55. Maugeri, N., de Gaetano, G., Barbanti, M., Donati, M., Cerletti, C. Prevention of platelet-polymorphonuclear leucocyte interactions: new clues to the antithroombotic properties of parnaparin, a low molecular weight heparin. Haematologica, 2005, 90, 833-839.
56. Born, G. V., Hume, M. Effects of the numbers and sizes of platelet aggregates on the optical density of plasma. Nature, 1967, 215, 1027-1029.
57. McBane, R. D., Karnicki, K, Tahirkheli, N., Miller, R. S., Owen, W. G. Platelet characteristics associated with coronary artery disease. J. Thromb. Haemos., 2003, 1, 1296-1303.
58. Glusa, E. Platelet aggregation in recombinant-hirudin-anticoagulated blood. Haemostasis, 1991, 21(Suppl 1), 116-20.
59. Storey, R. F., Wilcox, R. G., Heptinatall, S. Differential effects of glycoprotein IIb/IIIa antagonists on platelet microaggregate and macroaggregate formation and effect of anticoagulant on antagonist potency. Implications for assay methodology and comparison of different antagonists. Circulation, 1998, 98, 1616-1621.
60. Belcher, P. R., Drake-Holland, A. J., Hynd, J. W., Noble, M. I. M. Failure of thrombin inhibition to prevent intracoronary thrombosis in the dog. Clin. Sci., 1996, 90, 363-368.
61. Brass, L. F. In Haematology: Basic Principles and Practice, Hoffmann, R., Benz, J. E. J., Shattill, S. J. D., Furie, B., Cohen, H. J., Silbertson, L. E., Eds.; Churchill Livingstone: London, 1995, pp 1536-1552.
62. Pedvis, L. G., Wong, T., Frojmovic, M. M. Differential inhibition of the platelet activation sequence: shape change, micro- and macro-aggregation, by a stable prostacyclin analogue (Iloprost). Thromb. Haemos., 1988, 59, 323-8.
63. Jung, G., Razafindranaibe, F., Elkouby, A., Durasnel, P., Panes, F., Monassier, J. P. Modifications of platelet shape change and ATP release during cardiopulmonary bypass. Haemostasis, 1995, 25, 149-157.
64. Henn, V., Slupsky, J. R., Grafe, M., Anagnostopoulos, I., Forster, R., Muller-Berghaus, G., Kroczek, R. A. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature, 1998, 391, 591-594.
65. McEver, R. P., Martin, M. N. A monoclonal antibody to a membrane glycoprotein binds only to activated platelets. J. Biol. Chem., 1984, 259, 9799-9804.
66. Nieuwenhuis, H. K., van Oosterhout, J. J., Rozemuller, E., van Iwaarden, F., Sixma, J. J. Studies with a monoclonal antibody against activated platelets: evidence that a secreted 53,000-molecular weight lysosome-like granule protein is exposed on the surface of activated platelets in the circulation. Blood, 1987, 70, 838-845.
67. Hantgan, R. A study of the kinetics of ADP-triggered platelet shape change. Blood, 1984, 64, 896-906.
68. Milton, J., Frojmovic, M. Adrenaline and adenosine phosphate-induced platelet aggregation require shape change. Importance of pseudopods. J. Lab. Clin. Invest., 1984, 104, 805-815.
69. Verhoven, A., Gorter, G., Mommersteg, M., Akkerman, J. The energetics of early platelet responses. Biochem. J., 1995, 228, 451-462.
70. Heijen, H., van Lier, M., Waaienborg, S., Ohno-Iwashita, Y., Waheed, A., Innomata, M., Gorter, G., Mobius, W., Akkerman, J. W. N., Slot, J. W. Concentrations of raft in platelet filopodia correlates with recruitment of c-Src and CD63 to these domains. J. Thromb. Haemos., 2003, 1, 1161-1173.
71. Fabre, J., Nguyen, M., Latour, A., Keifer, J., Audoly, L., Coffman, T., Koller, B. Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice. Nature Medicine, 1999, 10, 1199-1202.
72. Ohlmann, P., Eckly, A., Mangin, P., Lanza, F., Gachet, C. Further evidence that fibrillar collagen in unable to promote platelet shape change and aggregation in the absence of secondary agonists. J. Thromb. Haemos., 2005, 3, 119-121.
73. 2 receptors. Am. J. Physiol., 1991, 260, H327-H334.
74. Maurer-Spurgej, E., Devine, D. Platelet aggregation is not initiated by platelet shape change. Lab. Invest., 2001, 81, 1517-1525.
75. Shattil, S., Newman, P. Integrins: dynamic scaffolds for adhesion and signaling in platelets. Blood, 2004, 104, 1606-1615.
76. Ingerman-Wojenski, C., Smith, J. B., Silver, M. J. Evaluation of electrical aggregometry: comparison with optical aggregometry, secretion of ATP, and accumulation of radiolabeled platelets. J. Lab. Clin. Invest., 1983, 101, 44-52.
77. Riess, H., Braun, G., Brehm, G., Hiller, E. Critical evaluation of platelet aggregation in whole human blood. Am. J. Clin. Path., 1986, 85, 50-56.
78. Thompson, N. T., Scrutton, M. C., Wallis, R. B. Particle volume changes associated with light transmittance changes in the platelet aggregometer: dependence upon aggregating agent and effectiveness of stimulus. Thromb. Res., 1986, 41, 615-626.
79. Charo, I. F., Feinman, R. D., Detwiler, T. C. Interrelations of platelet aggregation and secretion. J. Clin. Invest., 1977, 60, 866-873.
80. Menys, V. C., Belcher, P. R., Noble, M. I. M., Drossos, G. E., Pillai, R., Westaby, S. Impaired platelet aggregation after cardiopulmonary bypass in man: enhancement of collagen-induced aggregation in whole blood and plasma by adrenaline ex vivo. Clin. Sci., 1995, 88, 269-275.
81. Menys, V. C., Belcher, P. R., Noble, M. I. M., Evans, R. D., Drossos, G. E., Pillai, R., Westaby, S. Macroaggregation of platelets in plasma, as distinct from microaggregation in whole blood (and plasma), as determined by optical aggregometry and platelet counting respectively, is specifically impaired following cardiopulmonary bypass in man. Thromb. Haemos., 1994, 72, 511-518.
82. Menys, V. C., Smith, C. C. T., Lewins, P., Farmer, R. D. T., Noble, M. I. M. Platelet 5-hydroxytryptamine is decreased in a preliminary group of depressed patients receiving the 5-hydroxytryptamine re-uptake inhibiting drug fluoxetine. Clin. Sci., 1996, 91, 87-92.
83. von Pape, K. W., Aland, E., Bohner, J. Platelet function analysis with PFA-100 in patients medicated with acetylsalicylic acid strongly depends on concentration of sodium citrate used for anticoagulation of blood sample. Thromb. Res., 2000, 98, 295-299.
84. Favoloro, E. J. Utility of the PFA-100 for assessing bleeding disorders and monitoring therapy: a review of analytical variables, benefits and limitations. Haemophilia, 2001, 7, 170-179.
85. Steinhubl, S. R., Berger, P. B., Mann, J. T. I., Fry, E. T., DeLago, A., Wilmer, C., Topol, E. J., Credo Investigators. Clopidogrel for the Reduction of Events During Observation: Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomised controlled trial. JAMA, 2002, 288, 2411-2420 Erratum vol 289, pp. 987.
86. Wheeler, G. L., Braden, G. A., Steinhubl, S. R., Kereiakes, D. J., Kottke-Marchant, K., Michelson, A. D., Furman, M. I., Mueller, M. N., Moliterno, D. J., Sane, D. C. The Ultegra rapid platelet function assay: Comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy. Am. Heart. J., 2002, 143, 602-611.
87. Stejskal, D., Proskova, J., Petrzelova, A., Bartek, J., Oral, I., Lacnak, B., Horalik, D., Sekaninova, S. Application of cationic propyl gallate as inducer of thrombocyte aggregation for evaluation of effectiveness of antiaggregation therapy. Biomed. Papers, 2001, 145, 69-74.
88. Serebruany, V. L., Malinin, A. I., Oshrine, B. R., Sane, D. C., Takserman, A., Atar, D., Hennekens, C. H. Lack of uniform platelet activation in patients after ischaemic stroke and choice of antiplatelet therapy. Thromb. Res., 2004, 113, 197-204.
89. Fox, S. C., Sasae, R., Janson, S., Mat, J. A., Heptinstall, S. Quantitation of platelet aggregation and microaggregate formation in whole blood by flow cytometry. Platelets, 2004, 15, 85-93.
90. Hickerson, D. H., Bode, A. P. Flow cytometry of platelets for clinical analysis. Hematol. Oncol. Clin. N. Am., 2002, 16, 421-454.
91. Michelson, A. D. Flow cytometry: a clinical test of platelet function. Blood, 1996, 87, 4925-4936.
92. Harrison, P. Platelet function analysis. Blood Rev., 2005, 19, 111-123.
93. Folts, J. D., Rowe, G. G. Epinephrine potentiation of in-vivo stimuli reverses aspirin inhibition of platelet thrombus formation in stenosed canine coronary arteries. Thromb. Res., 1988, 50, 516-518.
94. McAuliffe, S. J. G., Snow, H. M., Smith, C. C. T., Noble, M. I. M. Interaction between effects of 5-hydroxytryptamine and adrenaline on the growth of platelet thrombi in the coronary artery of the anaesthetised dog. Br. J. Pharmacol., 1993, 109, 405-410.
95. Belcher, P. R., Drake-Holland, A. J., Hynd, J., Noble, M. I. M. Dispersion of coronary artery thrombi by antagonism of platelet serotonin receptor in the dog. Cardiovasc. Res., 1992, 26, 292-296.
96. Coller, B. S., Folts, J. D., Smith, S. R., Scudder, L. E., Jordan, R. Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GPIIb/IIIa receptor. Correlation with bleeding time, platelet aggregation, and blockade of GPIIb/IIIa receptors. Circulation, 1989, 80, 1766-1774.
97. 2 receptor antagonist ritanserin. Cardiovasc. Res., 1990, 24, 465-470.
98. Faichney, A., Davidson, K. G., Wheatley, D. J., Davidson, J. F., Walker, I. D. Prostacyclin in cardiopulmonary bypass operations. J. Thorac. Cardiovasc. Surg., 1982, 84, 601-8.
99. Kisch-Wedel, H., Kemming, G., Meisner, F., Flondor, M., Kuebler, W. M., Bruhn, S., Koehler, C., Zwissler, B. T. The prostaglandins epoprostenol and iloprost increase left ventricular contractility in vivo. Intens. Care Med., 2003, 29, 1574-83.
100. Burgaud, J. L., Ongini, E., Del Soldato, P. Nitric oxide-releasing drugs - A novel class of effective and safe therapeutic agents. Nitric oxide: novel actions, deleterious and clinical potential. Ann. N.Y. Acad. Sci., 2002, 962, 360-371.
101. Carini, M., Aldini, G., Orioli, M., Piccoli, A., Rossom, G., Facino, R. M. Nitric oxide release and distributiom following oral and intraperitoneal administration of nitroaspirin (NCX 4016) in the rat. Life Sci., 2004, 74, 3291-3305.
102. Momi, S., Pitchford, S., Alberti, P., Minuz, P., Del Soldato, P., Gresele, P. Nitroaspirin plus clopidogrel versus aspirin plus clopidogrel against platelet trhomboembolism and intimal thickening in mice. Thromb. Haemos., 2005, 84, 535-453.
103. Wainwright, C. Statins - is there no end to their usefulness? Cardiovasc. Res., 2005, 65, 296-298.
104. Serebruany, V., Malinin, A., Oshrine, B., Sane, D., Taskerman, A., Atar, D., Hennekens, C. Lack of uniform platelet activation in patients after ischemic stroke and choice of antiplatelet therapy. Thromb. Res., 2004, 113, 197-204.
105. Sack, E.,Quiroga, E. The variability of platelet-collagen interaction. Its influence on aspirin-induced inhibition of platelet aggregation. Thromb. Haemos., 1976, 35, 658-668.
106. de la Cruz, J., Bellido, I., Camara, S., Martos, F., Sanchez de la Cuesta, F. Effects of salicylic acid on platelet aggregation in male and female whole blood: an in vitro study. Scand. J. Haemotol., 1986, 36, 394-397.
107. Pulcinelli, F., Pignatelli, P., Celestini, A., Riondino, S., Gazzaniga, P., Violi, F. Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. J. Am. Coll. Cardiol., 2004, 43, 979-984.
108. Schwartz, K., Scwartz, D., Ghoseh, K., Reeves, M., Barber, K., de Franco, A. Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am. J. Cordiol., 2005, 95, 973-975.
109. Eikelboom, J. W., Hirsh, J., Weitz, J. I., Johnson, M., Qilong, Y., Yusuf, S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation, 2004, 105, 1650-1655.
110. Kawasaki, T., Ozeki, Y., Igawa, T., Kambayashi, J. Increased platelet sensitivity to collagen in individuals resistant to low-dose aspirin. Stroke, 2000, 31, 591-595.
111. de Gaetano, G., Donati, M., Cerletti, C. Prevention of thrombosis and vascular inflammation: benefits and limitations of selective or combined COX-1, COX-2 and 5-LOX inhibitors. Trends Pharmacol. Sci., 2003, 24, 245-252.
112. Montalescot, G., Barragan, P., Wittenberg, O., Ecollan, P., Elhada, S., Villain, P., Boulenc, J. M., Morice, M. C., Maillard, L., Pansieri, M., Choussat, R., Pinton, P., ADMIRAL-Investigators. Abciximab before direct angioplasty and stenting in myocardial infarction regarding acute and long-term follow-up. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N. Engl. J. Med., 2001, 344, 1895-1903.
113. Buttner, H. J., Neumann, F.-J. Tirofiban for catheter intervention in acute myocardial infarction. Eur. H. J., 2004, 25, 807-809.
114. FitzGerald, D. J. Platelet inhibition with an antibody to glycoprotein IIb/IIIa. Circulation, 1989, 80, 1918-1919.
115. Gibson, C., Jennings, L. K., Murphy, S. A., Lorenz, D., Guigliano, R., Harrington, R., Cholera, S., Krishnan, R., Califf, R., Braunwald, E. Association between platelet receptor occupancy after eptifibade (integrilin) therapy and patency, myocardial perfusion, and ST-segment resolution among patients with ST-segment-elevation mypcardial infacrtion. Circulation, 2004, 110, 679-684.
116. Serebruany, V. L., Malinin, A. I., Eisert, R. M., Sane, D. C. Risk of bleeding complications with antiplatelet agents: meta-analysis of 338,191 patients enrolled in 50 randomized controlled trials. Am. J. Hamatol., 2004, 75, 40-47.
117. 2-adrenergic receptor antagonist yohimbine inhibits epinephrine-induced platelet aggregation in healthy subjects. Clin. Pharmaacol. Ther., 1991, 49, 362-369.
118. Goto, S., Handa, S., Takahashi, E., Abe, S., Handa, M., Ikeda, Y. Synergistic effect of epinephrine and shearing on platelet activation. Thromb. Res., 1996, 84, 351-359.
119. Wagner, C. T., Kroll, M. H., Chow, T. W., Hellums, J. D., Schafer, A. L. Epinephrine and shear stress synergistically induce platelet aggregation via a mechanism that partially bypasses vWF-GP-Ib interactions. Biorheology, 1996, 33, 209-229.
120. Soulet, C., Sauzeau, V., Plantavid, M., Herbert, J. M., Pacaud, P., Payrastre, B., Savi, P. Gi-dependent and -independent mechanisms downstream of the P2Y12 ADP-receptor. J. Thromb. Haemos., 2004, 2, 135-146.
121. Paul, B. Z., Kim, S., Dangelmaier, C., Nagaswami, C., Jin, J., Hartwig, J. H., Weisel, J. W., Daniel, J. L., Kunapuli, S. P. Dynamic regulation of microtubule coils in ADP-induced platelet shape change by p160ROCK (Rho-kinase). Platelets, 2003, 14, 159-169.
122. Wilde, J. I., Retzer, M., Siess, W., Watson, S. P. ADP-induced platelet shape change: an investigation of the signalling pathways involved and their dependence on the method of platelet preparation. Platelets, 2000, 11, 286-295.
123. Missy, K., Plantavid, M., Pacaud, P., Viala, C., Chap, H., Payrastre, B. Rho-kinase is involved in the sustained phosphorylation of myosin and the irreversible platelet aggregation induced by PAR1 activating peptide. Thromb. Haemos., 2001, 85, 514-520.
124. Takano, K., Asazuma, N., Satoh, K., Yatomi, Y., Ozaki, Y. Collagen-induced generation of platelet-derived microparticles in whole blood is dependent on ADP released from red blood cells and calcium ions. Platelets, 2004, 15, 223-229.
125. Larson, M. K., Chen, H., Kahn, M. L., Taylor, A. M., Fabre, J. E., Nortensen, R. M., Conley, P. B., Parise, L. V. Identification of P2Y12-dependent and -independent mechanisms of glycoprotein VI-mediated Rap1 activation in platelets. Blood 2003, 101, 1409-1415.
126. Wihlborg, A. K., Wang, L., Braun, O. O.,Eyjolfsson, A., Gustafsson, R., Gudbjartsson, T., Erlinge, D. ADP receptor P2Y12 is expressed in vascular smooth muscle and stimulates contraction in human blood vessels. Arterio. Thromb. Haemos. Vasc. Biol., 2004, 24, 1810-1815.
127. Glyn, M. C., Lawrenson, J. G., Ward, B. J. A Rho-associated kinase mitigates reperfusion-induced change in the shape of cardiac capillary endothelial cells in situ. Cardiovasc. Res., 2003, 57, 195-206.
128. Martin, C., Goggel, R., Ressmeyer, A. R., Uhlig, S. Pressor responses to platelet-activating factor and thromboxane are mediated by Rho-kinase. Am. J. Physiol., 2004, 287, L250-257.
129. Clopidogrel-Trialists. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med, 2001, 345, 494-502, Erratum on 1716.
130. Sabatine, M. S., Cannon, C. P., Ginson, M., Lopez-Sendon, J. L., Montalescot, G., Theroux, P., Claeys, M. J., Cools, F., Hill, K. A., Skene, A., McCabe, C. H., Braunwald, E., CLARITY-TIMI 28 Investigators Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N. Engl. J. Med, 2005, 352, 1179-1189.
131. Ford, I., Williams, D. Does the use of statins compromise the effectiveness of platelet inhibition by clopidogrel? (Editorial). Platelets, 2004, 15, 201-205.
132. Lau, W. C., Waskell, L. A., Watkins, P. B., Neer, C. J., Horowitz, K., Hopp, A. S., Tait, A. R., Carville, D. G., Guyer, K. E., Bates, E. R. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation, 2003, 107, 32-37.
133. Angiolillo, D. J., Fernandez-Ortiz, A., Bernardo, E., Ramirez, C., Sabate, M., Banuelos, C., Hernandez-Antolin, R., Escaned, J., Moreno, R., Alfonso, F., Macaya, C. High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. Eur. Heart. J., 2004, 25, 1903-1910.
134. Gorchkova, O., von Beckerath, N., Gawaz, M., Mocz, A., Joost, A., Shomig, A., Kastrati, A. Antiplatelet effects of a 600mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting. Eur. Heart. J., 2004, 25, 1898-1902.
135. Kapetanakis, E. I., Medlam, D. A., Boyce, S. W., Haile, E., Hill, P. C., Dullum, M. K., Bafi, A. S., Petro, K. R., Corso, P. J. Clopidogrel administration prior to coronary artery bypass grafting surgery: the cardiologist's panacea or the surgeon's headache? Eur. Heart. J., 2005, 26, 576-583.
136. Chu, M. W., Wilson, S. R. Does clopidogrel increase blood loss following coronary artery bypass surgery? Ann. Thorac. Surg., 2004, 78, 1536-1541.
137. Tanaka, K. A., Szlam, F., Kelly, A. B., Vega, J. D., Levy, H. Clopidogrel (Plavix) and cardiac surgical patients: implications for platelet function monitoring and postoperative bleeding. Platelets, 2004, 15, 325-332.
138. Heptinstall, S., Glenn, J. R., May, R. J., Storey, R. F., Wilcox, R. G. Clopidogrel resistance. Cath. Cardiovas. Interven., 2004, 63, 397-398.
139. Heart Advice I've been taking aspirin for 25 years, and clopidogrel for several years. I've had a number of heart attacks. You reported recently on people who can't benefit from aspirin, and I think I may be one of them. What should I do? Heart Advisor (United States,) 2004, 7, 8.
140. Bennett, C. L., Connors, J. M., Carwile, J. M., Moake, J. L., Bell, W. R., Taratolo, S. R., McCarthy, L. J., Sarode, R., Hatfield, A. J., Feldman, M. D., Davidson, C. J., Trai, H. M. Thrombotic thrombocytopenic purpura associated with clopidogrel. N. Engl. J. Med., 2000, 342, 1773-1777.
141. Elmi, F., Peacock, T., Schiavone, J. Isolated profound thrombocytopenie associated with clopidogrel. J. Invas. Cardiol., 2000, 12, 532-535.
142. 2-receptors and serotonin release: their role in human platelet aggregation. Life Sci., 1993, 53, 209-215.
143. Noble, M. I. M., Drake-Holland, A. J. The involvement of serotonin in the formation of thrombi at critical coronary artery stenoses in humans. Co. Art. Dis., 1990, 1, 675-679.
144. Noble, M. I. M., Drake-Holland, A. J. Evidence for a role of serotonin in initiation of coronary arterial thrombosis in dog and man. Clin. Physiol. Biochem., 1990, 8(suppl 3), 50-55.
145. Noble, M. I. M., Drake-Holland, A. J. The possible role of serotonin 5HT2 receptor antagonism in cardioprotection. Neth. J. Med., 1992, 41, 183-189.
146. Noble, M. I. M., Drake-Holland, A. J. Mini-review: The role of serotonin 5HT2 receptor antagonism in the control of coronary artery disease. Q. J. Med., 1994, 87, 11-16.
147. 2 receptor in the presence of thrombolysis. Internat. J. Cardiol., 1994, 43, 11-20.
148. Vikenes, K., Farstad, M., Nordrehaug, J. E. Serotonin is associated with coronary artery disease and cardiac events. Circulation, 1999, 100, 483-489.
149. 2A receptor gene in patients with non-fatal acute myocardial infarction. Atherosclerosis, 2000, 150, 143-148.
150. Ozdener, F., Gulbas, Z., Erol, K., Ozdemir, V. 5-Hydrohytryptamine-2A receptor gene (HTR 2A) candidate polymorphism (T 102 C): role for human platelet function under pharmacological challenge ex vivo. Meth. Find. Expl. Clin. Pharmacol., 2005, 27, 395-400.
151. Drake-Holland, A. J. Modification of coronary artery disease using antithrombotic therapy? J. Cardiovasc. Risk 1995, 2, 229-233.
152. Jackson, S. P., Schoenwaelder, S. M., Goncalves, I., Nesbitt, W. S., Yap, C. L., Wright, C. E., Kenche, V., Anderson, K. E., Dopheide, S. M., Yuan, Y., Sturgeon, S. A., Prabaharan, H., Thompson, P. E., Smith, G., Shepherd, P. R., Daniella, N., Kulkarni, S., Abbott, B., Saylik, D., Jones, C., Lu, L., Giuliano, S., Hugban, S. C., Angus, J. A., Robertson, A. D., Salem, H. PI 3-kinase p110ß: a new target for antithrombotic therapy. Nature Medicine, 2005, 10, 1038/nm1232.
153. Cohen, H. W., Gibson, G., Alderman, M. H. Excess risk of myocardial infarction in patients treated with antidepressant medication: association with use of tricyclic agents. Am. J. Med., 2000, 1082-1088.
154. Bakish, D., Cavazzoni, P., Chudzik, J., Ravindran, A., Hrdina, P. D. Effects of selective serotonin reuptake inhibitors on platelet serotonin parameters in major depressive disorder. Biol. Psychiat., 1997, 41, 184-190.
155. 2+ mobilization in platelets. Eur. J Pharmacol., 1995, 288, 373-377.
156. Glassman, A. H., O'Connor, C. M., Califf, R. M., Swedberg, K., Schwartz, P., Bigger, J. T. J., Krishnan, K. R., van Zyl, L. T., Swenson, J. R., Finkel, M. S., Landau, C., Shapiro, P. A. Sertraline treatment of major depression in patients with acute myocardial infarction or unstable angina. J.A.M.A., 2002, 288, 701-709.
157. 2+ mobilization in platelets. Eur. J. Pharmacol., 1995, 288, 373-377.
158. Markovitz, J. H., Shuster, J. L., Chitwood, W. S., May, R. S., Tolbert, L. C. Platelet activation in depression and effects of sertraline treatment: an open-label study. Am. J. Psychiat., 2000, 157, 1006-1008.
159. Meier, C. R., Schlienger, R. G., Jick, H. Use of selective serotonin reuptake inhibitors and risk of developing first-time acute myocardial infarction. B. J. Clin Pharmacol., 2001, 52, 179-184.
160. Serebruany, V., Glassman, A., Malinin, A., Sane, D., Finkel, M., Krishnan, R., Atar, D., Lekht, A., O'Connor, C. Enhanced platelet/ endothelial activation in depressed patients with acute coronary syndromes: evidence from recent clinical trials. Blood Coag. Fibrinol., 2003, 14, 563-567.
161. (3H)paroxetine binding sites in platelets from depressed patients. J. Aff. Dis., 1999, 52, 225-233.
162. Pandey, G., Pandey, S., Janicek, P., Marks, R., Davis, J. Platelet serotonin-2 receptor binding sites in depression and suicide. Biol. Psychiat., 1990, 28, 215-222.
163. 2 receptor stimulation in platelets of depressed patients. Biol. Psychiat., 1993, 34, 565-568.
164. Serebruany, V., Glassman, A., Malinin, A., Nemeroff, C., Musselman, D., van Zyl, L., Finkel, M., Krishnan, K., Gaffney, M., Harrison, W., Califf, R., O'Connor, C. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake in hibitor sertraline after acute coronary events. Circulation, 2003, 108, 939-944.
165. Sauer, W., Berlin, J., Kimmel, S. Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction. Circulation, 2003, 108, 32-36.
166. Ashton, J. H., Benedict, C. R., Fitzgerald, C., Raheja, S., Taylor, A., Campbell, W. B., Buja, L. M., Willerson, J. T. Serotonin as a mediator of cyclic flow variations in stenosed canine coronary arteries. Circulation, 1986, 73, 572-578.
167. 2 receptor blockade provide protection against epinephrine-induced cyclic flow variations in severely narrowed canine coronary arteries. J. Am Coll. Cardiol., 1989, 13, 755-63.
168. Grover, G. J., Parham C.S, Youssef S,M.I., O. Protective effect of the serotonin receptor antagonist cinanserin in two canine models of pacing-induced myocardial ischaemia. Pharmacol., 1995, 50, 286-297.
169. Golino, P., Piscione, F., Willerson, J. T., Capelli-Bigazzi, M., Foraccio, A., Villari, B. I., Indolfi, C., Russolillo, E., Condorelli, M., Chiarello, M. Divergent effects of serotonin on coronary artery dimensions and blood flow in patients with coronary atherosclerosis and control patients. N. Engl. J. Med., 1991, 324, 641-648.
170. Chalmers, T. C., Murray, G. D. Retrospective analyses for hypothesis generation. A commentary on the PACK trial (prevention of atherosclerotic complications with ketanserin). Clin. Expl. Hyperten., 1989, 11, 1117-1136.
171. Saini, H. K., Takeda, N., Goyal, R. K., Kumamoto, H., Arneja, A. S., Dhalla, N. S. Therapeutic potentials of sarpogrelate in cardiovascular disease. Cardiovas. Drug Rev., 2004, 22, 27-54.